AstraZeneca PLC

AstraZeneca has launched a new AI-driven biologics discovery collaboration with Carterra, announced ahead of trading on 9 October 2026. The partnership links AstraZeneca's AI models with Carterra's high-throughput biosensor instruments to create autonomous, lab-in-the-loop discovery workflows. The project focuses on large molecule biologics, aiming to shorten experimental decision cycles and scale up antibody and protein engineering campaigns. AstraZeneca, which operates at a £186.1 billion market cap scale, is betting that the tie-up supports the premise that heavier spending on technologies like AI will translate into faster, more targeted drug launches and stronger earnings power. The unresolved question is whether such AI collaborations can offset pressure from patent expiries, price controls and high core R&D spend, especially as competitors like Pfizer and Merck also wire AI into their discovery lines.

Guardant Health announced that Guardant360 CDx has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH, also known as camizestrant, in advanced ER-positive breast cancer. The test identifies patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from the next-generation oral selective estrogen receptor degrader and complete ER antagonist. Using a simple blood draw, clinicians can test for ESR1 mutations ahead of disease progression, and the European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan. The clearance marks the third companion diagnostic approval for ETCAMAH and the 31st companion diagnostic approval for Guardant Health. Chairman and co-CEO Helmy Eltoukhy said the company sees tremendous potential for this testing protocol to transform the treatment of other cancer types.

AstraZeneca has applied to the US Food and Drug Administration for approval of ORPATHYS-TAGRISSO, a combination developed with HUTCHMED for advanced lung cancer that has progressed during or after EGFR-targeted therapy. The filing is supported by the 338-patient Phase 3 SAFFRON trial, which showed statistically significant improvements in both progression-free survival and overall survival, and the opportunity is meaningful because approximately 34% of tumors develop high levels of MET overexpression or amplification after progression. If approved, the combination would expand the use of Tagrisso, AstraZeneca's key oncology medicine, which recorded a 6% increase in second-quarter sales to $1.94 billion; the ORPATHYS-Tagrisso combination is already approved in China for a specified EGFR-mutated lung cancer population, so US approval could expand its geographic reach. The addressable population is narrower than Tagrisso's broader market, however, and even with approval the combination is unlikely to materially alter the current earnings profile in the near term. AstraZeneca closed at $156.90 on October 2, trading at approximately 15x forward earnings and 23.5x trailing earnings, with management targeting $80 billion in annual revenue by 2030, about 6.4% annual growth from the $58.7 billion generated in 2025.

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score technology, known as PrGIS, with AstraZeneca. PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients, and Myriad's proprietary MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad's PrGIS technology, drawing on a cloud-based platform with more than 1,000 connected institutions in over 75 countries. Myriad also plans to present PrGIS research co-authored with AstraZeneca at the European Society for Medical Oncology Congress 2026, with full data available after the ESMO embargo period.

Ironwood Pharmaceuticals raised its 2026 total revenue guidance to $460-$485 million from a prior range of $450-$475 million, citing continued prescription demand for its sole marketed product Linzess. Ironwood's share of net profit from Linzess sales in the United States surged 72.6% year over year during the first six months of 2026, and management expects mid-single-digit demand growth for the full year. Linzess, developed and commercialized in the United States through an equal profit-and-loss partnership with AbbVie, also generates royalties for Ironwood from Astellas Pharma in Japan and AstraZeneca in China. A recent FDA approval expanding Linzess' use in pediatric patients with functional constipation, where no FDA-approved prescription pediatric therapies previously existed, adds a further growth opportunity ahead of the company's third-quarter results. Earlier this year Ironwood reduced Linzess' list price to support patient access, and management expects lower mandatory government rebates to drive higher net revenues through 2026. The Zacks Consensus Estimate for 2026 earnings per share has risen to $1.10 from $1.04 over the past 60 days.

Carterra announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the-loop drug discovery. The effort brings together scientific and technical expertise to connect laboratory systems, software and data infrastructure with AI-driven discovery workflows. Lab-in-the-loop is the model in which AI systems propose drug candidates, wet-lab experiments generate data to test those predictions, and the resulting data feeds back to refine the next round of AI-guided design. Carterra's engineering and software teams are working with AstraZeneca's scientists and automation experts to create laboratory systems capable of generating standardized data at scale, with software designed to make that data directly usable in AI and machine learning workflows. Josh Eckman, CEO of Carterra, said AstraZeneca brings deep experience running biologics discovery at scale, and that its willingness to commit real scientific and automation resources reflects how urgently the field is moving toward a truly connected, AI-enabled discovery loop.

AstraZeneca has opened a new US$1b global research and development center in Kendall Square, Massachusetts, consolidating its US work in oncology, cell therapy, chronic and rare diseases, and obesity into a single expanded hub. The site uses robotics and AI-enabled automation to support the company's research programs and broader drug development efforts. AstraZeneca is a GB-based biopharmaceutical group with a £185.5 billion market cap that spends heavily on discovering and developing prescription medicines. The company said the center tightens the link between early science and late-stage assets, which could affect how quickly it refines drug candidates and retires weaker programs. Investors will be watching for Phase II or Phase III readouts in obesity, COPD and key oncology programs over 2027 to 2029 as markers of whether the build-out is translating into a more resilient portfolio mix.

Multiply Labs announced a $75 million Series B round, bringing its total capital raised to over $100 million since its founding in 2016. The round was led by Dr. Patrick Soon-Shiong with NantWorks, joined by new investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures, alongside returning investors Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund. The San Francisco-based physical AI company automates biologics manufacturing with robotic clusters that integrate into existing instruments and processes without requiring a new facility, delivering a 74% reduction in cost per dose and up to 100 times more throughput than manual manufacturing. Beginning with cell and gene therapy and now expanding to advanced biologics including antibodies, viral vectors, and mRNA, the platform is owned and operated directly by pharmaceutical and biologics companies rather than run as an outsourced service. Multiply Labs will use the capital to expand manufacturing capacity, accelerate its product roadmap, and scale its team across engineering, regulatory, and commercial functions as it moves from clinical-stage deployments toward commercial-scale production.

Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.

Summit Therapeutics announced the closing of AstraZeneca's $2.0 billion strategic equity investment in the company. Under the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the day the investment was announced. The proceeds will support accelerated development of ivonescimab, a potential first-in-class investigational PD-1 / VEGF bispecific antibody, across solid tumor settings including combinations with antibody drug conjugates such as sonesitatug vedotin and Datroway. Summit Chairman and Co-Chief Executive Officer Robert W. Duggan said the investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment. Baker Hostetler LLP is serving as legal advisor to Summit.

Nvidia's board authorized an additional $150B for its existing share-repurchase program, bringing the remaining authorization to $235B, which the company said was the largest increase to a share-repurchase authorization in history. Micron Technology reported fiscal fourth-quarter results and guidance that topped Wall Street's expectations by a wide margin, earning an adjusted $33.42 per share as revenue soared 379.1% year-over-year to $54.23B, versus analyst expectations of $31.72 per share on $51.49B in revenue. Accenture shares rose after its Q4 beat expectations and it forecast upbeat fiscal 2027 revenue growth, reporting GAAP earnings of $3.29 per share, revenue up 6.3% year over year to $18.7B, and new bookings of $22.2B. MongoDB shares fell after CEO Chirantan Desai stepped down effective immediately to become the newly created Chief Enterprise Platform Officer at Meta, with the board appointing Dev Ittycheria as interim president and CEO. Summit Therapeutics shares surged after AstraZeneca announced a $2B equity investment in the U.S. biotech and a clinical collaboration to develop new cancer treatments, purchasing convertible preferred shares at a conversion price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. For the week, the Dow fell 1.26%, the S&P 500 lost 0.27%, and the Nasdaq Composite climbed 0.45%.

AstraZeneca said the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemotherapy, a group with limited treatment choices. Priority Review shortens the FDA review timeline for this regimen, reflecting the agency's view that it may offer a meaningful clinical advance. AstraZeneca, a £192.8 billion pharmaceuticals group focused on prescription medicines, has been building its oncology presence across several tumour types, so any potential label expansion for IMFINZI touches a core therapy area rather than a side project for the business.

AstraZeneca has filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. The filing comes as the company's shares have fallen 10.29% over 90 days and 8.56% year to date, though the 1 year total shareholder return of 13.04% and 5 year total shareholder return of 55.73% remain positive. The most followed analyst narrative puts fair value at £159.11 against a last close of £124.28, implying 22% undervaluation, with 206 investors backing that view. Management estimates its late-stage pipeline across oncology, rare diseases, and cardiovascular and metabolic therapies could generate $10+ billion in peak risk-adjusted revenue. Risks to the rerating include tighter drug pricing regimes in key markets and heavier pressure on blockbuster franchises as competition builds.

On September 29, Summit announced that AstraZeneca will make a strategic equity investment of $2 billion in the company and will take the lead in advancing clinical research on ivonescimab combined with AstraZeneca's Sonesitatug Vedotin for the treatment of multiple gastrointestinal tumors. The two parties also plan to further promote clinical exploration of combination therapies involving ivonescimab and a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by this news, innovative drug concept stocks were repeatedly active in early trading on September 30. CanSino Biologics hit the 20-cent daily limit up, Berry Genomics hit the daily limit up, and Sino Biological, Tri-Prime Gene, and Walvax Biotechnology quickly followed with gains. On the same day, China's three major A-share indices opened collectively higher. As of press time, the Shanghai Composite Index rose 0.35 percent, the Shenzhen Component Index rose 0.48 percent, the ChiNext Index rose 0.92 percent, and the SSE STAR 50 Composite Index rose 0.31 percent. By sector, biotechnology, power generation equipment, and gas were relatively active, while the real estate sector led declines, and internet, semiconductor, and software sectors fluctuated in adjustment.

Dizal Pharmaceutical announced that on July 14, 2026, it signed a license agreement with AstraZeneca, granting AstraZeneca exclusive global rights to develop and commercialize sunvozertinib. The agreement took effect on August 31, 2026, and the company recently received a $600 million upfront payment from AstraZeneca. Boosted by this news, as of 10:09 a.m. on September 30, 2026, the underlying index of the Penghua STAR Market Healthcare ETF, the SSE STAR Market Biomedical Index, rose 2.85%, with constituent stocks CanSino Biologics up 20.00%, Vazyme up 11.89%, and Anhui Huaheng Biotechnology up 8.45%. The underlying index of the Penghua Hong Kong Stock Connect Healthcare ETF, the CSI Hong Kong Stock Connect Healthcare Composite Index, rose 2.16%. In addition, the latest post-hoc analysis of the Phase 3 clinical study in China of telitacicept for generalized myasthenia gravis, published on September 29, showed that more than 94% of patients achieved at least a 5-point improvement in MG-ADL score, and among patients who achieved MSE, 86.7% maintained MSE status at the next monthly assessment. Orient Securities pointed out that improving industry profit margins and the ramp-up of innovative products are jointly driving profit release, with CXO and innovative biologics becoming the strongest boom sectors. If innovative drugs continue to deliver profits in the second half of the year and CXO orders smoothly translate into revenue, the market's pricing logic for the pharmaceutical sector is expected to shift from low-valuation repair to a reassessment of the earnings sustainability of high-quality growth assets.

Hengrui Medicine announced that it has signed a licensing agreement with Novo Nordisk for the HRS-1596 project, granting the global weight-loss drug leader Novo Nordisk rights to its independently developed HRS-1596. The potential total transaction value is up to 2.6 billion US dollars, marking another step forward for Chinese innovative drug companies in the global weight-loss sector. On the same day, Dizal Pharmaceutical announced that it recently received a 600 million US dollar upfront payment from AstraZeneca. Boosted by this news, on September 30, the medical services concept rose 3.22 percent intraday, Yiqiao Shenzhou rose 13.14 percent, Nanmo Bio rose 10.70 percent, Berry Genomics rose 10.02 percent, Biopsychus rose 8.02 percent, and PharmaBlock Sciences rose 5.61 percent. Industrial Securities believes that innovation plus globalization remains the main theme for the pharmaceutical sector throughout the year. Multinational pharmaceutical companies facing patent cliffs need external pipelines, while domestic drug companies' R&D efficiency advantages are becoming more prominent, and cooperation models are upgrading, representing an increase in China's innovative voice.

AstraZeneca agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations, a stake that would give the biopharmaceutical company rights equivalent to roughly 12% of Summit's outstanding common shares. The companies plan to test AstraZeneca's sonesitatug vedotin alongside Summit's ivonescimab in gastrointestinal cancers, with each retaining the rights to its own medicine and room to pursue a broader clinical program if the partnership delivers. AstraZeneca shares were down about 0.7% at $164.95 at 9.55am EST on Tuesday. At that price, AstraZeneca trades 9.24% below its $181.75 GF Value estimate.

AstraZeneca agreed to make a $2 billion strategic equity investment in Summit Therapeutics, sending the biopharmaceutical company's shares up 17.1% in premarket trading. The investment supports a collaboration combining Summit's flagship bispecific antibody, ivonescimab, with AstraZeneca's oncology pipeline, and AstraZeneca will acquire convertible preferred shares at a price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Fair Isaac tumbled 15% after the Federal Housing Finance Agency announced changes to mortgage pricing that will introduce competition to FICO's longstanding role in the mortgage credit-scoring market; FHFA Director Bill Pulte said Fannie Mae and Freddie Mac will consolidate their separate pricing matrices into a single unified grid that will incorporate VantageScore alongside the traditional FICO Classic score. CarMax rose 3.7% after reporting fiscal second-quarter earnings of $1.16 per share, beating analyst expectations of 68 cents, with revenue of $7.88 billion topping forecasts of about $7.06 billion. AAR Corp. surged 6.9% after announcing an agreement to acquire a 65% controlling interest in MRO Holdings at an implied enterprise value of $4 billion, alongside adjusted diluted EPS of $1.49 and revenue of $918 million that beat expectations. Netflix rose 1.4% after Deutsche Bank upgraded the streaming giant to Buy from Hold with a $95 price target, while AbCellera Biologics gained 2.1% on a JPMorgan Overweight initiation with a $17 price target and Q32 Bio rose 9.4% ahead of a key clinical data presentation at the European Academy of Dermatology and Venereology Congress in Vienna beginning Sept. 30.

AstraZeneca announced a $2B equity investment in Summit Therapeutics and a clinical collaboration to develop new cancer treatments, sending Summit shares up 24%. Under the deal, AstraZeneca will purchase convertible preferred shares at a conversion price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Sangoma Technologies shares soared 35% after the company agreed to be acquired by an affiliate of BRC Group Holdings in a transaction valuing the firm at approximately $204M in enterprise value, with shareholders receiving $4.925 in cash plus 0.04767 of a BRC share per Sangoma share, implying total consideration of $5.225 per share. Navitas Semiconductor jumped 14% after saying it was selected by the U.S. federal government to develop next-generation 10 kV silicon carbide power semiconductor technology under the Army's ALATTIS program. Pharming shares slipped 2% after CEO and executive director Fabrice Chouraqui stepped down with immediate effect, with Chief Commercial Officer Leverne Marsh and CFO Kenneth Lynard appointed interim co-CEOs.

AstraZeneca has invested two billion US dollars, or £1.5 billion, in US pharmaceutical firm Summit Therapeutics as part of a cancer treatment research joint venture. The equity investment will help speed up development of Summit's experimental drug ivonescimab, which targets specific proteins to attack cancer cells and stop them growing. The two firms will collaborate on the medicine and research how it could be combined with AstraZeneca's treatments, particularly its sonesitatug vedotin drug, with trials in gastrointestinal cancer to begin imminently. Each company will contribute its respective medicine for the planned combination trials and jointly fund trial costs, while retaining development and commercial rights to its own medicines. Summit's shares soared by nearly a fifth after markets closed overnight in New York, while AstraZeneca's shares were 2% higher on Tuesday morning in London.

Dizal Pharmaceutical announced that it has received a $600 million upfront payment from AstraZeneca. Previously, on July 14, 2026, the two parties signed a license agreement for sunvozertinib, under which Dizal Pharmaceutical granted AstraZeneca exclusive global rights to develop and commercialize sunvozertinib. In addition to the $600 million upfront payment, the company will also receive up to $900 million in milestone payments tied to specific clinical development, regulatory approval, and sales achievements, as well as tiered royalties on global sales. Dizal Pharmaceutical said the funds have effectively strengthened its cash reserves and are expected to have a positive impact on its 2026 results and financial position. Sunvozertinib is an oral, irreversible, highly selective tyrosine kinase inhibitor independently developed by the company. Its use as a monotherapy in second-line and later settings for EGFR exon 20 insertion mutation non-small cell lung cancer has been approved in both China and the United States, and AstraZeneca will commercialize the drug in the U.S. in the fourth quarter of this year. In the first half of 2026, the company achieved operating revenue of 523 million yuan, up 47.24% year on year, while the net loss attributable to shareholders of the listed company was 210 million yuan, narrowing the loss by 167 million yuan compared with the same period last year.

China's innovative drug industry has welcomed another major licensing deal. Shanghai Sprout and Merck jointly announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor, with a potential total value of $2.13 billion, including an upfront payment of $400 million, with the remainder tied to development and commercialization milestones. Meanwhile, Summit Therapeutics, the overseas partner of Akeso, announced that AstraZeneca will make a $2 billion strategic equity investment in Summit and intends to lead clinical exploration of Akeso's first-in-class tumor immunotherapy 2.0 cornerstone drug ivonescimab in combination with AstraZeneca's Sonesitatug Vedotin for treating multiple gastrointestinal tumors. The two parties also signed a memorandum of understanding to further advance clinical exploration of ivonescimab combined with a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by the news, as of 10:01 a.m. on September 29, 2026, the STAR Market Biotech ETF managed by Penghua Fund, with ticker 588250, saw its underlying index, the SSE STAR Market Biomedical Index with code 000683, rise 1.10%. Among constituents, InventisBio rose 5.16%, Micro-Tech Nanjing rose 3.84%, Hotgen Biotech rose 3.13%, and Huiyu Pharmaceutical and Yound Biotechnology followed the gains. China Securities pointed out that the medical device sector has reached an inflection point in 2026, and stocks with improving performance are expected to see dual recovery in valuation and earnings. High-value consumables and in-vitro diagnostics segments are expected to gradually clear the impact of centralized procurement price cuts in the second half of the year, and leaders in niche tracks will accelerate growth.

AstraZeneca has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS, or savolitinib, plus TAGRISSO, or osimertinib, for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have MET overexpression or amplification and who progressed on or after an EGFR tyrosine kinase inhibitor therapy, HUTCHMED announced. The filing is supported by the global SAFFRON Phase III trial, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free survival and overall survival in this setting, versus doublet platinum-based chemotherapy in patients who progressed on TAGRISSO. SAFFRON enrolled 338 patients across 230 centers in 29 countries and builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials, with results to be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology Congress 2026. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca; the combination is already approved in China based on SACHI and received a temporary authorization in Switzerland based on SAVANNAH. Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said the filing is an important step toward potentially bringing the biomarker-directed, chemotherapy-free oral combination to patients in the US.

Eccogene has received a $50 million milestone payment from AstraZeneca, triggered by the initiation of the global Phase 3 clinical program for elecoglipron, also known as AZD5004 or ECC5004. Elecoglipron is an investigational once-daily oral small molecule GLP-1 receptor agonist discovered by Eccogene and licensed to AstraZeneca outside Greater China in November 2023. The Phase 3 program includes the Embold trials in obesity or overweight with and without type 2 diabetes, the Eluminate trials in type 2 diabetes as monotherapy and in combination with dapagliflozin, and two Elevate outcome trials in heart failure with mildly reduced or preserved ejection fraction and chronic kidney disease. The Phase 3 start follows positive topline results from the Phase 2b VISTA and SOLSTICE trials, which showed 11.8% weight loss at 36 weeks in adults with obesity or overweight and a 1.9% HbA1c reduction at 26 weeks in adults with type 2 diabetes. Eccogene has now earned $295 million to date under the collaboration and remains eligible for future milestones and royalties, with the original deal including a $185 million upfront payment and up to $1.825 billion in total clinical, regulatory and commercial milestones.

AstraZeneca announced Wednesday that the European Commission approved its inhaler therapy Trixeo Aerosphere as a late-line maintenance option for asthma patients aged 12 years and older, expanding the drug's availability in the EU. The decision specifically covers patients whose symptoms remain insufficiently controlled despite prior therapy with a combination of a medium-dose inhaled corticosteroid and a long-acting beta2-agonist. Marketed as Breztri Aerosphere in the U.S., the triple-combination therapy is already available there for adults with chronic obstructive pulmonary disease. The latest approval follows a positive opinion in July from an expert panel of the EU drug regulator recommending the label expansion for asthma, a condition affecting nearly 43 million people in Europe.

AstraZeneca received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use for Enhertu and Klygefa in the European Union. The committee backed Enhertu as an adjuvant treatment option for early-stage HER2-positive breast cancer with a high risk of recurrence. It also supported Klygefa as an add-on therapy for generalised myasthenia gravis, targeting patients with a rare autoimmune condition. The next concrete waypoint for investors is the formal European Commission decisions following these September 2026 CHMP opinions, including the exact labels granted for Enhertu and Klygefa in the EU. Those label details and the timing of the decisions will shape how far AstraZeneca can extend usage into high-risk early breast cancer and anti-acetylcholine receptor positive gMG in the first wave of launches.

The AI Structural Biology Network, powered by Apheris, launched AISB Bind, a federated initiative in which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson will collaboratively train an AI model to predict how small molecules bind to protein targets for virtual screening and lead optimization. The new initiative extends the network's first effort, which focused on protein-ligand structure prediction, where a co-folding model fine-tuned across more than 20,000 proprietary structures from active drug-discovery programs raised the share of high-quality predictions from 36% to 52%, outperforming public models and any model fine-tuned on a single partner's data alone. In AISB Bind, the four founding partners contribute three complementary types of data: experimentally determined structures, quantitative affinity and potency measurements, and high-throughput screening activity data, the last adding a large body of confirmed non-binders that is rarely available at industrial scale. Training runs through federated learning, so each partner's proprietary data stays within its own secure environment, with Apheris hosting the network and running the training and each partner receiving the resulting model to run and further tailor internally. Federated training begins in September 2026, with final models expected in early 2027, powered by the infrastructure of Apheris's technology partner, Amazon Web Services.

AstraZeneca and Daiichi Sankyo's Enhertu has been cleared for use by England's National Health Service for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE's revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices, and around 1,000 women in England are expected to benefit annually. Enhertu carries a list price of £1,455 per 100 mg vial, although the financial terms agreed with NICE were not disclosed, and NICE cited clinical evidence showing a six-month survival benefit for some patients. The decision expands access in one of Europe's largest healthcare markets and comes as Enhertu is already a significant growth driver: combined sales reported by AstraZeneca and Daiichi Sankyo reached $2.96 billion in the first half of 2026, up 29% from $2.29 billion a year earlier, while AstraZeneca's own H1 alliance revenue from Enhertu rose to $1.06 billion from $834 million. In Europe, AstraZeneca reported $401 million of Enhertu revenue, up 28%, and combined global sales increased 36% in FY2025 to $4.98 billion, with AstraZeneca's alliance revenue reaching $1.80 billion versus $1.44 billion in 2024. The direct financial contribution from England may remain relatively limited given the roughly 1,000 patients expected annually and the undisclosed commercial terms, making the incremental revenue, margin, or cash-flow benefit difficult to quantify.

AstraZeneca announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of its rare-disease drug Klygefa, also known as gefurulimab, as an add-on therapy for adults with generalised myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. If approved, Klygefa would become the first and only dual-binding nanobody C5 inhibitor for that patient population in the European Union. The drug is already approved in Japan and certain other countries for specific adults with gMG, and is under regulatory review in the United States, China and some other countries for the same indication. The CHMP recommendation was supported by positive data from the pivotal phase III PREVAIL study, which met its primary endpoint by showing a treatment difference of -1.6 in the myasthenia gravis activities of daily living score at week 26 versus placebo, with clinically meaningful improvement seen as early as week one and sustained through week 26. About 85% of people living with gMG are AChR antibody-positive, and across five major European countries an estimated 82,500 people have gMG, including approximately 66,000 AChR antibody-positive patients.

AstraZeneca said the FDA accepted its regulatory filing for the investigational enzyme replacement therapy efzimfotase alfa in patients aged two years and older with hypophosphatasia, or HPP, and granted the application priority review, shortening the review period by four months, with a final decision expected during the first half of 2027. The filing is supported by data from three phase III studies: MULBERRY met its primary endpoint in treatment-naive children aged two to less than 12 years old, showing a significant improvement in bone health, and CHESTNUT showed that patients switching from Strensiq could maintain the benefits of treatment, while HICKORY did not meet its primary endpoint in treatment-naive individuals aged 12 years and older, though AstraZeneca reported a numerical improvement, particularly in patients with pediatric-onset disease. The company said efzimfotase alfa was generally well-tolerated with an acceptable safety profile across the three studies. The commercial angle rests on Strensiq, the established HPP treatment AstraZeneca gained through its 2021 acquisition of Alexion, which was approved by the FDA in 2015 as the first bone-targeted enzyme replacement therapy for HPP and generated $1.05 billion in sales in the first half of 2026, up 41% year over year. Efzimfotase alfa is designed to require lower injection volumes and substantially less frequent dosing, once every two weeks, compared with Strensiq's three- or six-times-weekly regimen. Elsewhere in the space, BioMarin Pharmaceutical entered HPP through its acquisition of Alesta Therapeutics, completed earlier this month, paying $275 million upfront with up to $215 million in additional milestone payments for ALE1, an oral small-molecule therapy in a phase I/IIa study, while Recursion Pharmaceuticals is developing the oral ENPP1 inhibitor REC-102, formerly REV102, which remains in IND-enabling studies with a data-driven decision on a phase I study expected before the end of this year.

AstraZeneca and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy, with 14.3 months median progression free survival and a 37% risk reduction versus pembrolizumab plus chemotherapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in late-stage trials, with a 29% to 34% exacerbation reduction. Management has pointed to more than US$10b in potential peak risk adjusted revenue from new drugs, and investors will focus on US and EU COPD approval decisions ahead of the first quarter of 2027 Prescription Drug User Fee Act date. The article was produced by Simply Wall St.

AstraZeneca PLC released full results from two successful late-stage trials of tozorakimab, an experimental chronic obstructive pulmonary disease drug that reduced moderate and severe flare-ups by roughly 30% across a broad patient population. The two trials showed reductions in moderate-to-severe COPD exacerbations of 29% to 34%, with the highest-eosinophil subgroup seeing a 43% reduction, and benefits appearing regardless of eosinophil levels, smoking status, or disease severity. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027, and AstraZeneca forecasts more than $5 billion in peak annual sales, an estimate CEO Pascal Soriot said the drug's commercial potential could exceed. AstraZeneca believes tozorakimab could reach a broader group of COPD patients than existing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala, which only target those with high eosinophil counts. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year, as AstraZeneca targets $80 billion in annual revenue by 2030, though the drug still needs FDA approval and faces patent-expiry pressure on established products including Farxiga and Brilinta.

London stocks closed higher on Thursday, September 17, with the FTSE 100 ending at 10,816.14 points, up 127.67 points, or 1.19%, hitting its highest level in more than a week. The gain came after the Bank of England voted 6 to 3 to keep interest rates at 3.75%, in line with market expectations, and announced it would suspend sales of UK government bonds for six months and halt long-dated bond sales altogether. The move followed a global bond selloff just days earlier that pushed the UK's 30-year borrowing cost to 5.96%, its highest since 1998. BoE Governor Andrew Bailey warned that prolonged conflict in the Middle East could make tighter monetary policy necessary. Data from LSEG showed investors had already priced in at least a 0.25% rate hike from the BoE this year. Rate-sensitive bank shares rose 1.6%, with HSBC and Standard Chartered leading the market with gains of 2% and 2.2% respectively. AstraZeneca rose about 2.4% after Chinese authorities said they would invest nearly 200 million yuan, or 29.81 million dollars, to upgrade its manufacturing base and supply chain in the city of Wuxi. Bytes Technology surged 12% after stronger-than-expected first-half results and an upgrade to its full-year gross profit growth forecast.

Onco360 has been selected by AstraZeneca as a national pharmacy partner for Etcamah, also known as camizestrant, the company announced. The therapy is indicated for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. Etcamah is an estrogen receptor antagonist that binds to the ligand-binding domain of ERα, antagonizing both wild-type and mutated ESR1 and inducing proteasome-dependent degradation of ERα without agonizing it. Its approval was based on the phase 3 SERENA-6 study, in which Etcamah plus a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus an aromatase inhibitor plus a CDK4/6 inhibitor, with median PFS of 16 months versus 9.2 months and a hazard ratio of 0.44. The most common adverse reactions, occurring in at least 20% of patients, included decreased neutrophils, leukocytes, hemoglobin, lymphocytes and platelets, along with visual disturbances and fatigue.

The FDA granted accelerated approval to AstraZeneca's camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer, Bloomberg reported on September 5, 2026, despite an FDA advisory panel voting in April that the drug lacked patient benefit. The approval covers use alongside a CDK4/6 inhibitor for patients with an ESR1 gene mutation, based on a Phase III trial showing the combination cut the risk of disease progression or death by 56% compared with standard treatment. Median progression-free survival reached 16 months versus 9.2 months with standard treatment. Etcamah is already approved in more than 30 countries and is projected to make over $5 billion in peak annual sales. The accelerated approval requires AstraZeneca to complete confirmatory studies, and the Oncologic Drugs Advisory Committee voted 6-3 against the drug's risk-benefit profile in April, with several members questioning the trial design and whether the treatment would provide long-term benefit.